GLP-1RA Exposure and Nonarteritic Anterior Ischemic Optic Neuropathy Prevalence by Diabetes Status.
作者信息
Nagdeve Pallavi, Griffin Russell
机构信息
Department of Ophthalmology and Visual Sciences, School of Medicine, University of Alabama, Birmingham.
Department of Epidemiology, School of Public Health, University of Alabama, Birmingham.
出版信息
JAMA Ophthalmol. 2025 Jul 24. doi: 10.1001/jamaophthalmol.2025.2332.
Abstract
摘要
相似文献
1
GLP-1RA Exposure and Nonarteritic Anterior Ischemic Optic Neuropathy Prevalence by Diabetes Status.按糖尿病状态划分的胰高血糖素样肽-1受体激动剂暴露情况与非动脉炎性前部缺血性视神经病变患病率
JAMA Ophthalmol. 2025 Jul 24. doi: 10.1001/jamaophthalmol.2025.2332.
2
Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy.司美格鲁肽与非动脉炎性前部缺血性视神经病变
JAMA Ophthalmol. 2025 Apr 1;143(4):304-314. doi: 10.1001/jamaophthalmol.2024.6555.
3
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide.司美格鲁肽处方治疗患者发生非动脉炎性前部缺血性视神经病变的风险。
JAMA Ophthalmol. 2024 Aug 1;142(8):732-739. doi: 10.1001/jamaophthalmol.2024.2296.
4
The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy.司美格鲁肽和胰高血糖素样肽-1受体激动剂对非动脉性前部缺血性视神经病变风险的影响。
Am J Ophthalmol. 2025 Jun;274:24-31. doi: 10.1016/j.ajo.2025.02.025. Epub 2025 Feb 25.
5
GLP-1RA-Associated Diabetic Lumbosacral Radiculoplexus and Common Fibular Neuropathies: A Case-Control Evaluation.胰高血糖素样肽-1受体激动剂相关的糖尿病性腰骶神经根丛神经病和腓总神经病：一项病例对照评估
Neurology. 2025 Aug 12;105(3):e213916. doi: 10.1212/WNL.0000000000213916. Epub 2025 Jul 22.
6
Association between Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy: A Multinational Population-Based Study.司美格鲁肽与非动脉炎性前部缺血性视神经病变之间的关联：一项基于多国人群的研究。
Ophthalmology. 2025 Apr;132(4):381-388. doi: 10.1016/j.ophtha.2024.10.030. Epub 2024 Nov 2.
7
Semaglutide: Nonarteritic Anterior Ischemic Optic Neuropathy in the FDA adverse event reporting system - A disproportionality analysis.司美格鲁肽：美国食品药品监督管理局不良事件报告系统中的非动脉炎性前部缺血性视神经病变——一项不成比例分析。
Obes Res Clin Pract. 2025 Jan-Feb;19(1):77-79. doi: 10.1016/j.orcp.2025.01.011. Epub 2025 Feb 7.
8
Nonarteritic Anterior Ischemic Optic Neuropathy in Black Patients.黑人患者的非动脉炎性前部缺血性视神经病变
Am J Ophthalmol. 2025 Feb;270:192-202. doi: 10.1016/j.ajo.2024.09.036. Epub 2024 Oct 15.
9
Nonarteritic Anterior Ischemic Optic Neuropathy and Semaglutide: What is This All About?非动脉炎性前部缺血性视神经病变与司美格鲁肽：这是怎么回事？
J Assoc Physicians India. 2024 Aug;72(8):11-12. doi: 10.59556/japi.72.0621.
10
Disproportionality analysis on semaglutide and nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system: An emerging pharmacovigilance signal?在FDA不良事件报告系统中对司美格鲁肽与非动脉炎性前部缺血性视神经病变进行的不成比例分析：一个新出现的药物警戒信号？
Obes Res Clin Pract. 2025 Mar-Apr;19(2):178-180. doi: 10.1016/j.orcp.2025.03.001. Epub 2025 Mar 24.
本文引用的文献
1
Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: A Danish-Norwegian cohort study.司美格鲁肽的使用与非动脉炎性前部缺血性视神经病变风险：一项丹麦-挪威队列研究。
Diabetes Obes Metab. 2025 Jun;27(6):3094-3103. doi: 10.1111/dom.16316. Epub 2025 Mar 17.
2
Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy.司美格鲁肽与非动脉炎性前部缺血性视神经病变
JAMA Ophthalmol. 2025 Apr 1;143(4):304-314. doi: 10.1001/jamaophthalmol.2024.6555.
3
Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes.在丹麦一个由424152名2型糖尿病患者组成的队列中，每周一次的司美格鲁肽使非动脉炎性前部缺血性视神经病变的五年风险增加了一倍。
Int J Retina Vitreous. 2024 Dec 18;10(1):97. doi: 10.1186/s40942-024-00620-x.
4
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide.司美格鲁肽处方治疗患者发生非动脉炎性前部缺血性视神经病变的风险。
JAMA Ophthalmol. 2024 Aug 1;142(8):732-739. doi: 10.1001/jamaophthalmol.2024.2296.
5
Incidence of nonarteritic anterior ischemic optic neuropathy: increased risk among diabetic patients.非动脉炎性前部缺血性视神经病变的发病率：糖尿病患者的风险增加。
Ophthalmology. 2011 May;118(5):959-63. doi: 10.1016/j.ophtha.2011.01.054. Epub 2011 Mar 24.
Zotero 插件